Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CK-3773274 dose-finding study in symptomatic hypertrophic cardiomyopathy
NL-OMON52672Phase 2Not yet recruiting
- Sponsor
- Cytokinetics
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aficamten in hypertrophic cardiomyopathy (HCM) (3 arms), sponsored by Cytokinetics. Primary endpoints: Incidence of adverse events, Incidence of serious adverse events and 1 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
aficamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NL-OMON52672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52672.